Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Johnson n Johnson...

    Johnson n Johnson Slapped Rs 213 crore over lawsuit of Benadryl and other OTC drugs

    Written by Ruby Khatun Khatun Published On 2017-05-27T11:41:36+05:30  |  Updated On 27 May 2017 11:41 AM IST
    Johnson n Johnson Slapped Rs 213 crore over lawsuit of Benadryl and other OTC drugs
    US: Johnson & Johnson has agreed to pay $33 million which is almost Rs. 213 crore to resolve charges by most U.S. states that it misrepresented the manufacturing practices behind Tylenol, Motrin, Benadryl and other over-the-counter drugs that were eventually recalled.

    The settlement, announced by attorneys general for 42 states and the District of Columbia, resolves claims related to several products, including children's medicines, that were voluntarily recalled from 2009 to 2011.


    The list includes St. Joseph Aspirin, Sudafed, Pepcid, Mylanta, Rolaids, Zyrtec, and Zyrtec Eye Drops, the Illinois attorney general said in a news release.


    The company's Johnson & Johnson Consumer Inc unit must also ensure that its marketing and promotional practices do not unlawfully promote over-the-counter drug products, the attorneys general said.


    The accord followed a string of recalls of millions of packages of drugs made by J&J's McNeil-PPC Inc unit, now part of Johnson & Johnson Consumer, over faulty manufacturing.


    According to the state attorneys general, McNeil put on the market batches of drugs that failed to comply with federal standards and were deemed adulterated as a matter of federal law.


    They claimed that McNeil misrepresented its compliance federal manufacturing rules and the quality of its over-the-counter drugs.


    "Johnson & Johnson's disregard for proper manufacturing practices of children's medications was unacceptable," Illinois Attorney General Lisa Madigan said in a statement.


    In a statement, J&J said that its "recalls were precautionary and not undertaken on the basis of any health or safety risks to consumers, and we remain committed to providing consumers with safe and effective over-the-counter medicines."


    J&J's McNeil unit previously in 2015 pleaded guilty to selling liquid medicine contaminated with metal and agreed to pay $25 million to resolve a U.S. Justice Department investigation.


    (Reporting by Nate Raymond in Boston; Editing by Chizu Nomiyama and David Gregorio)

    AspirinBenadrylIllinois AttorneyJohnson & JohnsonlawsuitMotrinMylantaOver the counter drugsPepcidpharma newsRolaidsSudafedTylenolZyrtecZyrtec Eye Drops
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok